EudraGMP Homepage      
 
 
MIA | GMP | API REG | WDA | GDP | Sites Help
Tue 10 Nov 2026 15:19:52 BST
GMP Compliance Menu 
Search
GMP Certificates
Non-Compliance Report


Print Preview
                  
Print Preview (Short version)
                  
Back To Search

 

Austrian Agency For Health And Food Safety

CERTIFICATE NUMBER: 482009-101919969

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1) , (2)

Part 1

Issued following an inspection in accordance with
Art. 15 of Directive 2001/20/EC as amended
Art. 80(5) of Directive 2001/82/EC as amended
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Austria confirms the following:

The manufacturer: Polymun Scientific Immunbiologische Forschung GmbH

Site address: Donaustrasse 99, Klosterneuburg, Lower Austria, 3400, Austria

OMS Organisation Id. / OMS Location Id.: ORG-100009761 / LOC-100018022


Other

(Human) API-A80(1)-D2001/82/EC,API-A111(1)-D2001/83/EC,NIP-A40-D2001/83/EC

(Veterinary) NIP-A44-D2001/82/EC

(Investigational product) NIP-A13-D2001/20/EC


From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on  2021-05-27 , it is considered that it complies with: 
  • The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product categories stated in Part 2. (3)
  • The principles and guidelines of Good Manufacturing Practice laid down in Directive 91/412/EEC. (3)  

  • This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (https://eudragmdp.ema.europa.eu/). This certificate is valid only when presented with all pages and both Parts 1 and 2.

     The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

    __________________________________________________________________________________________________________________________
    (1) The certificate referred to in paragraph Art. 15 of Directive 2001/20/EC, Art. 80(5) of Directive 2001/82/EC and Art. 111(5) of Directive 2001/83/ECis also applicable to importers.
    (2) Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.
    (3) These requirements fulfil the GMP recommendations of WHO.

    Part 2

    Human Medicinal Products
    Human Investigational Medicinal Products
    Veterinary Medicinal Products

    1  MANUFACTURING OPERATIONS
    1.1  Sterile products
       1.1.1  Aseptically prepared (processing operations for the following dosage forms)
               1.1.1.1  Large volume liquids
               1.1.1.2  Lyophilisates
               1.1.1.4  Small volume liquids
       1.1.3  Batch certification
    1.2  Non-sterile products
       1.2.1  Non-sterile products (processing operations for the following dosage forms)
               1.2.1.11  Semi-solids
       1.2.2  Batch certification
    1.3  Biological medicinal products (list of product types)
       1.3.1  Biological medicinal products (list of product types)
               1.3.1.8  Other: Native konjugierte und nicht konjuguerte rekombinante monoklonale Antikörper, rekombinante Antigene, Hormone und Enzyme / Native conjugated and non-conjugated recombinant monoclonal antibodies, recombinant antigens, hormones and enzymes, Native und rekombinante monoklonale Antikörper, rekombinante Antigene, Hormone und Enzyme / Native and recombinant monoclonal antibodies, recombinant antigens, hormones and enzymes(en)
       1.3.2  Batch Certification (list of product types)
               1.3.2.8  Other: Native konjugierte und nicht konjuguerte rekombinante monoklonale Antikörper, rekombinante Antigene, Hormone und Enzyme / Native conjugated and non-conjugated recombinant monoclonal antibodies, recombinant antigens, hormones and enzymes, Native und rekombinante monoklonale Antikörper, rekombinante Antigene, Hormone und Enzyme / Native and recombinant monoclonal antibodies, recombinant antigens, hormones and enzymes(en)
    1.4  Other products or manufacturing activity
       1.4.1  Manufacture of
               1.4.1.3  Other: Liposomale Formulierungen von Wirkstoffen, Lipidnanopartikel (LNPs) / Liposomal formulation of active substances, Lipidnanoparticles (LNPs), Liposomale Formulierungen von Wirkstoffen, Lipidnanopartikel (LNPs) / Liposomal formulation of active substances, Lipidnanoparticles (LNPs)ngen von Wirkstoffen / Liposomal formulation of active substances(en)
    1.5  Packaging
       1.5.1  Primary Packaging
               1.5.1.11  Semi-solids
       1.5.2  Secondary packaging
    1.6  Quality control testing
       1.6.2  Microbiological: non-sterility
       1.6.3  Chemical/Physical
       1.6.4  Biological

    2  IMPORTATION OF MEDICINAL PRODUCTS
    2.1  Quality control testing of imported medicinal products
       2.1.2  Microbiological: non-sterility
       2.1.3  Chemical/Physical
       2.1.4  Biological

    Manufacture of active substance. Names of substances subject to inspection:
    [900000005420]recombinant proteins and enzymes(en)
    [900000005419]monoclonal antibodies(en)
    [900000005417]recombinant human erythropoietin (C4C2)(en)
    [900000005418]recombinante human follicle-stimulating hormone (rhFSH)(en)

    3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

    Active Substance:recombinant proteins and enzymes
    3.3 Manufacturing of Active Substance using Biological Processes
     
    3.3.1  Fermentation
    3.3.2  Cell Culture:
    mammalian
    3.3.3  Isolation / Purification
    3.3.4  Modification
    3.5 General Finishing Steps
     
    3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
    3.6 Quality Control Testing
     
    3.6.1  Physical / Chemical testing
    3.6.2  Microbiological testing excluding sterility testing
    3.6.4  Biological Testing

    Active Substance:monoclonal antibodies
    3.3 Manufacturing of Active Substance using Biological Processes
     
    3.3.1  Fermentation
    3.3.2  Cell Culture:
    mammalian
    3.3.3  Isolation / Purification
    3.3.4  Modification
    3.5 General Finishing Steps
     
    3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
    3.6 Quality Control Testing
     
    3.6.1  Physical / Chemical testing
    3.6.2  Microbiological testing excluding sterility testing
    3.6.4  Biological Testing

    Active Substance:recombinant human erythropoietin (C4C2)
    3.3 Manufacturing of Active Substance using Biological Processes
     
    3.3.1  Fermentation
    3.3.2  Cell Culture:
    mammalian
    3.3.3  Isolation / Purification
    3.3.5  Other:
    Zelltyp / cell type CHO
    3.5 General Finishing Steps
     
    3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
    3.6 Quality Control Testing
     
    3.6.1  Physical / Chemical testing
    3.6.2  Microbiological testing excluding sterility testing
    3.6.4  Biological Testing

    Active Substance:recombinante human follicle-stimulating hormone (rhFSH)
    3.3 Manufacturing of Active Substance using Biological Processes
     
    3.3.1  Fermentation
    3.3.2  Cell Culture:
    mammalian
    3.3.3  Isolation / Purification
    3.3.5  Other:
    Zelltyp / cell type CHO
    3.5 General Finishing Steps
     
    3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
    3.6 Quality Control Testing
     
    3.6.1  Physical / Chemical testing
    3.6.2  Microbiological testing excluding sterility testing
    3.6.4  Biological Testing

    Clarifying remarks (for public users):
    Polymun Scientific Immunbiologische Forschung GmbH; Probebetrieb bis / valid until: 11/2024; Ad 3.3.3: Separieren / Separation, Chromatographie / Chromatography, Fällung / Precipitation, Filtration / Filtration (gilt für beide Wirkstoffgruppen / valid for both Active substance groups); Ad 3.3.4: Koppeln / Conjugation; Die vollständige Liste der hergestellten und importierten Wirkstoffe ist dem Bundesamt für Sicherheit im Gesundheitswesen bekannt / The complete list of manufactured and imported Active Substances is available at the Austrian Federal Office for Safety in Health Care

     

     



     
     
     
         
     
     
     
     
    The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please click here to get list of NCA's.

    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI.

    Documents issued by UK authorities up to and including 31 December 2020 remain available for consultation in EudraGMDP. However, they are no longer included or updated from 1 January 2021, with the exception of the documents pertaining to sites located in Northern Ireland.

    [EMA © 2014. EudraGMDP 6.5.4.8 build 2026/01/16 09:45]